This is a preview of subscription content, log in via an institution to check access.
References
Bonnaud I, Spelle L, Rancurel G, Salama JZ, Moret J, Samson Y. [11C]-Flumazenil positron emission tomography in hemispheric stroke. J Neurol 2001; 248 (Suppl 2):II/33.
Kreisler A, Charpentier P, Lecouffe P, Defebvre L, Steinling M, Destée A. Corticobasal degeneration and Parkinson’s disease assessed by HMPAO SPECT. J Neurol 2001; 248 (Suppl 2):II/36.
Jasinska-Myga B, Ochudo S, Siuda J, Pietka E, Opala G. A comparative (99mTc)-HM-PAO SPECT study in Parkinson’s disease patients with and without dementia. J Neurol 2001; 248 (Suppl 2):II/80.
Gschwandtner U, Jakscha J, Maclachlan D, Nitzsche E, Freitag P, Steck AJ. Comparison of PET (positron emission tomography) and eye movement deficits in patients with minor cognitive deficits (MCD) due to neurological and rheumatological diseases. J Neurol 2001; 248 (Suppl 2):II/143.
Wiest R, Schindler K, Wissmeyer M, Lövblad K, Donati F, Weder B. Subtraction ictal SPECT (SISCOM) co-registrated to MRI in the presurgical evaluation of temporal and extratemporal epilepsies. J Neurol 2001; 248 (Suppl 2):II/189.
Henkel K, Kramer B, Ecker D, Karitzky J, Storch A, Sabolek M, Reske SN, Ludolph AC, Landwehrmeyer GB. CMraclopride-PET in early Huntington’s disease: in vivo evidence for a striatal dopamine D2 receptor down regulation and correlation of binding potentials with the clinical phenotype. J Neurol 2001; 248 (Suppl 2):II/191.
Karitzky J, Henkel K, Mader I, Neumaier B, Sabolek M, Grodd W, Reske SN, Ludolph AC, Landwehrmeyer GB. Neuroimaging in corticobasal degeneration: a multimodal approach to characterize cortical and subcortical neuronal and glial impairment in-vivo. J Neurol 2001; 248 (Suppl 2):II/192.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stokkel, M. News and views. Eur J Nucl Med 28, 1404 (2001). https://doi.org/10.1007/s002590100612
Published:
Issue Date:
DOI: https://doi.org/10.1007/s002590100612